858 Therapeutics Launches with Proven Team and $60 Million Series A Financing
Retrieved on:
Tuesday, September 21, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Biotechnology, Amira, Therapy, Cancer, Gene expression, Record, Protein, Inflammation, RNA, NEA, Patient, Versant, Genentech, Bristol Myers Squibb, Cormorant, Biology, Initial public offering, Series A round, CA, Technology, IPO, VP, Fine chemical, Pharmaceutical industry, Vaccine, 858 Therapeutics, Versant Ventures, NEA, 858 THERAPEUTICS, VERSANT VENTURES, NEA
858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.
Key Points:
- 858 Therapeutics today exited stealth mode with a $60 million Series A financing led by founding investor Versant Ventures, with participation from NEA, Cormorant Asset Management and Logos Capital.
- 858s founding team includes CEO Jeffrey Stafford, Ph.D., CSO James Veal, Ph.D., and VP of Biology Gretchen Bain, Ph.D.
- They previously held leadership roles at three other San Diego-based discovery companies co-founded by Versant including Jecure Therapeutics, Quanticel Pharmaceuticals and Amira Pharmaceuticals.
- With this financing, the company plans to expand its team to about 40 people within the next 18 months.